Aldevron News: Gene Editing

WEBINAR: CRISPR Genome Editing Solutions from Discovery to Clinic

Among current techniques for clinical genome editing, the CRISPR-associated gene editing system has emerged as a highly advantageous method to drive development of new gene and cell therapies. Through evolving routes of direct delivery of the CRISPR-ribonucleoprotein (RNP) complex, consisting of single guide RNA (sgRNA) and Cas nucleases, a non-viral approach has become increasingly in demand for gene-editing clinical trials. However, drug developers face significant challenges when initiating their clinical programs, which includes the design and production of the target-specific guides, the production of reliable, high-quality nucleases, and the ability to characterize the RNP complex for the efficient and safe delivery of a genomic therapy.
Read More

Aldevron, Jennifer Doudna, and Innovative Genomics Institute Collaborate on In Vivo CRISPR Therapies for Neurologic Diseases. Resulting paper published in Molecular Therapy.

FARGO, N.D. (August 29, 2023)Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, contributed to a publication in collaboration with 2020 Nobel Laureate Jennifer Doudna and the Innovative Genomics Institute (IGI) at the University of California, Berkeley to advance research on in vivo, CRISPR-based genome editing strategies to address genetic diseases of the central nervous system such as Huntington’s disease and ALS. Aldevron supplied custom CRISPR protein with ultra-low endotoxin, enabling direct delivery to the brain in mice. This partnership resulted in a paper, titled “Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs,” published in the journal Molecular Therapy, the official journal of the American Society of Gene and Cell Therapy.

Read More

Advancing Direct Enzyme Delivery for Therapeutic Genome Editing In Vivo

Genome editing enzymes such as Cas9 have been successfully employed to target different genetic disorders in model systems, and ex vivo approaches have demonstrated the clinical potential of this technology. However, the challenge of delivering such corrective enzymes in vivo represents a substantial barrier to therapeutic translation.  

Viral vectors—refined during their use in traditional gene therapy—represent the most widely-used delivery platform in preclinical work, and nanoparticles are quickly maturing into a comparably powerful vehicle. Direct delivery of pre-formed CRISPR enzymes has recently emerged as an appealing strategy for enabling therapeutic editing in vivo.  

Read More

In the News: Pharma's Almanac - The Pivotal Role of Plasmid DNA

Plasmid DNA was key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With its plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. The company continues to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.

Read More

Aldevron Releases GMP-Grade SpyFi™ Cas9 Nuclease

Product is the result of a partnership with Integrated DNA Technologies, Inc., and provides clinical stage clients with a critical raw material 

Aldevron is announcing the release of GMP SpyFi Cas9 Nuclease for clinical and commercial applications. SpyFi Cas9 Nuclease, the trade name for Aldevron’s research grade and GMP products, is the direct result of a partnership with Integrated DNA Technologies, Inc. (IDT). The advantages of SpyFi Cas9 Nuclease include reduced off-target effects combined with clinically relevant on-target activity.

Read More

Aldevron to Provide New GMP Cas9 Nuclease Through Agreement with Integrated DNA Technologies

Aldevron and Integrated DNA Technologies, Inc. (IDT), a supplier of custom nucleic acid and genome editing products, have announced a license agreement whereby Aldevron will manufacture and distribute a S. pyogenes Cas9 variant—known as SpyFiTM Cas9 Nuclease—which is patented by IDT. The product will be manufactured for research, clinical, and commercial use.  

Read More

Aldevron Announces Availability of GMP SpCas9

Aldevron, a leading global provider of contract plasmid DNA manufacturing, protein production and antibody discovery services, announces the availability of GMP-grade SpCas9 nuclease for use in clinical development programs.  Aldevron’s GMP SpCas9 is designed to accelerate gene editing clinical trials and commercial applications by providing an immediate enzyme supply; thereby eliminating months typically associated with contract GMP production and testing.

Read More